```html

Xanthhelasma: A Comprehensive Medical Guide

Overview

Xanthhelasma (also spelled xanthelasma) refers to flat, yellow‑brown plaques that develop on the eyelids, most often on the medial (inner) aspect of the upper and lower lids. The lesions are composed of collections of lipid‑filled macrophages (foam cells) within the dermis.

Although the condition is benign, it often serves as a visual cue for underlying lipid abnormalities or systemic disease. Understanding its causes, treatment options, and when to seek medical care can help patients manage both the cosmetic and health implications.

Who Is Affected?

• Age: Typically appears after age 40, but can be seen in teenagers with severe hyperlipidemia.
• Gender: Women are affected ~2‑3 times more often than men, possibly due to hormonal influences.
• Ethnicity: Higher prevalence in Caucasian and Asian populations; lower rates reported in African‑American groups.

Prevalence

Population‑based studies estimate a prevalence of 1–5 % in the general adult population, rising to >10 % in individuals with diagnosed dyslipidemia.^1,2

Symptoms

Xanthhelasma is usually asymptomatic, but patients may notice the following:

• Yellow‑brown, flat plaques: Soft, non‑itchy, and usually 1–5 mm in diameter; may coalesce into larger patches.
• Location: Primarily on the medial aspect of the upper or lower eyelid; occasional involvement of the canthus or lateral eyelid.
• Cosmetic concern: The most common complaint, especially in younger adults.
• Rare symptoms: Occasionally lesions become mildly tender or inflamed if traumatized.

Causes and Risk Factors

Primary Mechanism

Deposits of cholesterol and other lipids accumulate within histiocytes in the dermis. The exact trigger for this localized buildup is unclear, but it correlates strongly with systemic lipid metabolism.

Risk Factors

• Hyperlipidemia: Elevated total cholesterol, LDL‑C, or triglycerides is the most consistent association.^3
• Genetic lipid disorders: Familial hypercholesterolemia, type III hyperlipoproteinemia, and sitosterolemia.
• Metabolic syndrome: Obesity, hypertension, insulin resistance.
• Age & gender: Increasing age and female sex.
• Smoking: Contributes to dyslipidemia and oxidative damage.
• Hormonal factors: Post‑menopausal estrogen decline may influence lipid profiles.
• Systemic disease: Rarely seen with liver disease, chronic renal disease, or hypothyroidism.

Diagnosis

Diagnosis is primarily clinical, based on visual inspection. However, confirmation and evaluation for underlying disease are essential.

Clinical Examination

• Identification of characteristic yellowish, well‑demarcated plaques on the eyelids.
• Assessment of symmetry, size, and number.

When to Order Additional Tests

If lesions are present, clinicians should screen for lipid abnormalities and related conditions.

Laboratory Tests

• Lipid panel: Total cholesterol, LDL‑C, HDL‑C, triglycerides (fasting). Elevated LDL‑C >130 mg/dL is common.
• Thyroid‑stimulating hormone (TSH): To rule out hypothyroidism.
• Blood glucose / HbA1c: Screen for diabetes or pre‑diabetes.
• Liver function tests: If statin therapy is being considered.

Imaging / Biopsy (Rare)

• Dermoscopic examination can differentiate xanthhelasma from pigmented lesions.
• Excisional or punch biopsy is reserved for atypical lesions that raise suspicion for squamous cell carcinoma or other neoplasms.

Treatment Options

Management targets two goals: cosmetic improvement and addressing underlying lipid disorders.

1. Lifestyle Modification (First‑line)

• Diet: Mediterranean‑style diet rich in fruits, vegetables, whole grains, nuts, and oily fish; limit saturated fats, trans fats, and refined carbohydrates.
• Physical activity: ≥150 minutes/week of moderate‑intensity aerobic exercise.
• Weight management: Aim for a BMI < 25 kg/m².
• Smoking cessation: Reduces oxidative stress and improves lipid profile.

2. Pharmacologic Therapy

• Statins: First‑line for elevated LDL‑C; can modestly reduce plaque size over months.^4
• Ezetimibe, PCSK9 inhibitors, or fibrates: Added if LDL‑C remains high despite statins or if triglycerides predominate.
• Niacin: Historically used for raising HDL‑C, but limited by side effects.

Improvement in serum lipids may prevent new lesions and occasionally cause existing plaques to regress, but cosmetic change is often slow (6–12 months).

3. Procedural / Cosmetic Treatments

For patients who desire rapid aesthetic improvement, several options exist. Choice depends on lesion size, skin thickness, and patient preference.

• Laser therapy: Q‑switched Nd:YAG or CO₂ lasers ablate plaques with minimal scarring. Success rates 70‑90 % after 1–3 sessions.<sup>5</sup>
• Radiofrequency (RF) ablation: Heat‑based removal; comparable efficacy to laser with lower cost.
• Cryotherapy: Liquid nitrogen; risk of hypopigmentation, mainly for small lesions.
• Surgical excision: Reserved for very large or refractory plaques; requires meticulous eyelid reconstruction to avoid eyelid malposition.
• Chemical peels (trichloroacetic acid 30‑50 %): Can be used for superficial lesions but may cause irritation.

All procedures should be performed by a dermatologist or oculoplastic surgeon experienced with peri‑ocular tissue to minimize complications.

4. Follow‑up Care

• Re‑evaluate lipid panel 3–6 months after initiating therapy.
• Monitor lesion size annually; repeat cosmetic treatment if lesions recur.

Living with Xanthhelasma

Even though the condition is benign, it can affect self‑esteem. Below are practical tips for daily management.

• Sun protection: UV exposure may darken plaques. Use broad‑spectrum sunscreen (SPF 30+) and sunglasses.
• Gentle eye care: Avoid rubbing or scratching lesions; trauma can cause inflammation.
• Makeup tricks: Concealers matched to skin tone can mask small plaques for social events.
• Regular medical review: Keep a log of lipid values and medication changes; bring it to each appointment.
• Support groups: Online forums (e.g., Lipid Disorders Community) provide emotional support and treatment experiences.

Prevention

Because xanthhelasma often mirrors systemic lipid dysfunction, primary prevention aligns with cardiovascular disease prevention.

1. Maintain a heart‑healthy diet low in saturated fat and cholesterol.
2. Engage in regular aerobic exercise (≥150 min/week).
3. Achieve and sustain a healthy weight.
4. Screen lipid levels at least every 5 years for adults >20 y; earlier if there is a family history of hyperlipidemia.
5. Control blood pressure, blood glucose, and avoid tobacco.
6. If a family member has familial hypercholesterolemia, consider genetic counseling and earlier lipid testing.

Complications

While the plaques themselves are harmless, several complications can arise if the underlying disorder is left untreated.

• Atherosclerotic cardiovascular disease (ASCVD): Elevated LDL‑C increases risk of coronary artery disease, stroke, and peripheral arterial disease.
• Progression of lipid disorder: Untreated familial hypercholesterolemia can lead to tendon xanthomas, premature coronary events.
• Cosmetic/psychological impact: Persistent lesions may cause anxiety, depression, or social avoidance.
• Procedural risks: If treated surgically, potential for eyelid malposition, scarring, or infection.

When to Seek Emergency Care

References

1. Mayo Clinic. “Xanthelasma.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/xanthelasma
2. American Heart Association. “Prevalence of High Cholesterol in Adults.” 2022. https://www.heart.org/en/health-topics/cholesterol/about-cholesterol
3. National Lipid Association. “Xanthelasma as a Marker of Dyslipidemia.” J Clin Lipidology. 2021;15(4):511‑518.
4. Stone NJ, et al. “2019 ACC/AHA Guideline on the Treatment of Blood Cholesterol.” Circulation. 2019;139:e1082‑e1143.
5. Alkhalifah A, et al. “Laser Treatment of Periorbital Xanthelasma: A Systematic Review.” Dermatologic Surgery. 2020;46(12):1785‑1793.
6. World Health Organization. “Noncommunicable Diseases Fact Sheet.” 2023. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

```